{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-067495","form_type":"8-K","ticker":"BOLD","cik":"0001782303","company_name":"Boundless Bio, Inc.","filed_at":"2025-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.693717+00:00","generated_at":"2026-05-22T01:58:31.815900+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Boundless Bio reports Q1 2025 net loss $15.8M; $138.3M cash; BBI-355 data due H2 2025","bullets":["Cash, cash equivalents, and short-term investments totaled $138.3M as of March 31, 2025, providing runway into 2027.","Net loss of $15.8M for Q1 2025 versus $15.4M in Q1 2024; R&D expenses $12.1M ($13.1M Q1 2024), G&A $5.2M ($3.8M).","BBI-355 Phase 1/2 POTENTIATE trial enrollment ongoing; preliminary clinical proof-of-concept data expected second half 2025.","Novel Kinesin program: development candidate nomination expected mid-2025, IND filing planned for first half 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-067495","json":"https://secwatch.observer/filing/0000950170-25-067495.json","markdown":"https://secwatch.observer/filing/0000950170-25-067495.md","text":"https://secwatch.observer/filing/0000950170-25-067495.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782303/000095017025067495/0000950170-25-067495-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782303/000095017025067495/bold-20250509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T01:58:31.815900+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}